The global ibuprofen API market size was valued at USD 645.09 Million in 2022 and is projected to reach USD 841.70 Million by 2031, and is expected to expand at a CAGR of 3% during the forecast period, 2023–2031. The growth of the market is attributed to the rising prevalence of chronic diseases globally.
Ibuprofen is a type of nonsteroidal anti-inflammatory drug, which means it is used to treat inflammatory disease, mild to moderate pain, rheumatoid disorders, fever, dysmenorrhea, and osteoarthritis. Ibuprofen blocks the production of certain natural substances that cause inflammation.
Nonsteroidal anti-inflammatory medicines are a group of pharmaceuticals that have anti-inflammatory effects in addition to acting as analgesics (pain relievers) and antipyretics (fever reducers) in large dosages. Moreover, active pharmaceutical ingredients (APIs) are used as basic materials in pharmaceutical formulations which provide beneficial health effects.
Ibuprofen is an FDA-approved medicine used for fever reduction in children and adults. However, ibuprofen is not recommended to the elderly population, due to the danger of gastrointestinal bleeding and ulcers.
Ibuprofen needs to be taken every four to six hours, as it has a short-acting span. According to a clinical investigation undertaken by governments and non-governmental agencies, Ibuprofen causes headaches, nausea, dyspepsia, constipation, dizziness, and salt and fluid retention. Therefore, it is advised to not take the dosage of ibuprofen for more than 10 days at a time without consulting a doctor first.
It is quickly broken down and often leaves the body through pee within 24 hours. The suggested over-the-counter doses for treating arthritic pain in adults 12 years of age and older are 200-400 mg every four to six hours as needed, with a daily maximum of 1,200 milligrams.
Different dosages are recommended for kids 12 and under depending on the child’s weight. The suggested over-the-counter doses for treating arthritic pain in adults 12 years of age and older are 200–400 mg every four to six hours as needed, with a daily maximum of 1,200 milligrams.
The COVID-19 pandemic has significantly impacted the ibuprofen market. The majority of undertakings have been seriously impacted, except the clinical supply and life support item organization. The COVID-19 illness spread globally affecting countless people in total. Therefore, the governments imposed a lockdown, and now the lockdown restrictions have been loosened. Everything is slowly returning to normal.
In March 2020, no-steroidal anti-inflammatory medicines (NSAIDs), such as ibuprofen, were recommended to patients by the US Food and Drug Administration for COVID-19. It was proposed that an enzyme, whose activity is elevated by NSAIDs, is expected to exacerbate COVID-19 symptoms. However, according to a study published in the Journal of Clinical Microbiology and Infection in September 2020 titled “Ibuprofen use and clinical outcomes in COVID-19 patients”, ibuprofen use was not linked to worse clinical outcomes when compared to paracetamol or no antipyretic.
Ibuprofen API market Dynamics
The report presents a complete market overview, and market dynamics by focusing on the current market trends, existing drivers, growth opportunities, and emerging challenges that shape the outcome or overall performance of the market during the forecast period, 2023 to 2031.
Major Drivers
The research report finds that the increasing production of pharmaceuticals and biopharmaceuticals drives market growth during the forecast period. The market for ibuprofen is expanding, due to the rising chronic disease. Chronic disorders include cardiovascular conditions, cancer, chronic lung conditions, strokes, Alzheimer’s, diabetes, and chronic kidney disease. There are effective therapies that lead to the treatment of people with chronic illnesses that come with rising risks.
Primarily chronic disorders, infectious diseases, and kidney complications are becoming more common today. The rising occurrence of a wide range of illnesses among all age groups drives the need for medication development. Ibuprofen is safer and more effective than other NSAIDs such as aspirin. Ibuprofen is equally effective as aspirin and other NSAIDs in treating rheumatoid arthritis.
Arthritis is the term used to describe joint discomfort. Joint inflammation can cause swelling, stiffness, redness, and pain. An inflammatory condition called rheumatoid arthritis damages the joints of the body by inflaming them and making them painful. There are different types of arthritis, such as ankylosing spondylitis, lupus, osteoarthritis, gout, psoriatic arthritis, pseudogout, and others.
Existing Restraints
The rising production cost is anticipated to hamper the market growth during the forecast period. Companies increase their purchase from suppliers of the raw materials and commodities they require when customer demand is high. Thus, increased demand potentially leads to increased supplier pricing and production costs. For instance, in March producer prices increased 4.2% over the prior year, which represents the large growth since 2011.
A supply chain is hindered, due to the pandemic, shipping problems, winter storms, shipping problems, and delays. Moreover, manufacturers are unable to innovate in their manufacturing processes, due to the pressure of prices. Thus, the market stumbles behind in fully embracing advances allowed by technology.
Existing Opportunities
Research advancements in pain management and medical therapies are anticipated to propel the market growth. The healthcare industry has started to concentrate on auxiliary therapy options for muscular aches and pains. Medical professionals have trust in suggesting ibuprofen, owing to its effective and quick therapy mechanism. Ibuprofen API is advised as the first line of therapy by physicians.
Moreover, the use of ibuprofen in maternity care has increased the demand for ibuprofen API on a global scale. Ibuprofen’s popularity is due to its effectiveness in treating arthritic pain and the discomfort associated with menstruation. The usage of ibuprofen API has been strongly advocated by the medical profession in hospitals and other healthcare facilities.
There has been an increase in the use of cutting-edge technologies including bioinformatics, throughput, and combinatorial chemistry, for improved drug candidate identification. One of the popular drug discovery techniques is high-throughput screening, which is made possible by automation, multidetector readers, software, and imaging gear. Drug discovery has evolved significantly with emerging technologies, becoming a more precise, refined, and quick process.
Scope of Ibuprofen API market Report
The market report includes an assessment of the market trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
Ibuprofen API Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2022
|
|
Historic Data
|
2016–2021
|
|
Forecast Period
|
2023–2031
|
|
Segmentation
|
Application (Arthritis, Headache, and Others), and End-user (Pharmaceutical and biopharmaceutical Companies, Contract Research Organizations, and Contract Manufacturing Organizations)
|
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
Sino-US Zibo Xinhua-Perrigo Pharmaceutical Co., Ltd.; Solara Active Pharma Sciences Limited; Granules India Limited; BASF SE; BIOCAUSE Inc.; IOL Chemicals and Pharmaceuticals Limited; and SI Group, Inc.
|
Ibuprofen API market Segment Insights
Application Segment Analysis
On the basis of application, the ibuprofen API market is segmented into arthritis, headache, and others. The arthritis segment is projected to expand at a considerable CAGR during the forecast period. Arthritis is a common cause of pain and disability. There are many types of medications available for arthritis pain relief. Ibuprofen is effective in the treatment of rheumatoid arthritis at dosages of 1,200 mg/day or higher. A full glass of water is expected to be consumed with this drug orally, usually every 4 to 6 hours.
The dosage is based on the patient medical condition and treatment response. The dosage of ibuprofen for children is determined by their weight. The headache segment is anticipated to account for a major market share during the forecast period. Ibuprofen is recommended by the American Headache Society (AHS) as an effective first-line therapy for migraines in adults.
The research review found that ibuprofen effectively reduces mild to moderate migraine discomfort. According to studies, prostaglandins during a migraine attack induce inflammation of the blood vessels in the brain, which results in pain. Ibuprofen is anticipated to aid in the relief of pain by preventing the effect of prostaglandin. However, there is still a lot to discover regarding the origins of migraine attacks.
End-User Segment Analysis
Based on end-user, the market is divided into pharmaceutical & biopharmaceutical companies, contract research organizations, and contract manufacturing organizations. The pharmaceutical & biopharmaceutical companies segment is expected to hold a significant share of the market in the coming years.
Pharmaceutical businesses are increasing manufacturing costs and making significant R&D investments to keep ahead of the global competition. A variety of illnesses are fueling demand for the active pharmaceutical ingredient in ibuprofen, which is boosting pharmaceutical companies’ profits.
Ibuprofen is a non-steroidal anti-inflammatory medicine with great demand and potential for a big profit. The contract manufacturing organizations segment accounts for a significant market share. Major pharmaceutical companies strongly choose contract manufacturing firms to provide APIs and final formulations.
Contract manufacturing organization are reevaluating their approach to stay up with the shifting dynamics of the pharmaceutical industry, which include cost-cutting and improved differentiation from rivals.
Additionally, contract manufacturing is working together to offer packaged services. Supply chains for pharmaceutical companies are linked with contract manufacturing companies. In 2022, contract manufacturing organizations are anticipated to occupy 44.7% of the global market share, while pharmaceutical firms are projected to hold 55.5% of the market.
Regional Analysis
In terms of region, the ibuprofen API market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is expected to constitute a key share of the market during the forecast period, owing to the rising usage of nonsteroidal anti-inflammatory drugs and the strong footholds of top manufacturers.
The market in Europe for active pharmaceutical ingredients that contain ibuprofen is growing in sales due to the high demand and technological advances in manufacturing. The key factors that are anticipated to propel the market growth include the high prevalence of orthopedic disorders, growing urbanization, increased demand for pain relievers, more surgeries, and neuromuscular diseases such as arthritis and rising cancer cases.
The Asia Pacific is anticipated to expand at a rapid pace during the forecast period, due to rising healthcare expenditure. Moreover, the cheap cost of production in India and China has led to increased production facilities, luring global leaders in pharmaceutical and biotechnology to the Asia Pacific region.
The rising geriatric population is expected to boost the demand for novel pain relief as part of the therapy since the senior population is predisposed to suffering from several chronic ailments. According to the Indian Ministry of Statistics and Programme Implementation study “Elderly in India 2021”, which was released in July 2021, estimated that there were around 137.9 million individuals over the age of 60 living in India in 2021.
Healthcare activities with the treatment of rheumatoid arthritis require continuous support from everyone. The market in the Asia Pacific region is expected to grow, due to the rising incidence of rheumatoid arthritis disease and owing to the presence of key market players. In September 2021, Lupin, an India-based pharmaceutical company, introduced the authorized generic version of Duexis (famotidine and ibuprofen) Tablets for the treatment of the signs and symptoms of rheumatoid arthritis and osteoarthritis.
The generic version of Duexis Tablets is expected to reduce the risk of developing upper gastrointestinal ulcers, which were identified in clinical trials as gastric and/or duodenal ulcers in individuals using ibuprofen for such conditions.
Segments
The global ibuprofen API market has been segmented on the basis of
Application
- Arthritis
- Headache
- Others
End-user
- Pharmaceutical & Biopharmaceutical Companies
- Contract Research Organizations
- Contract Manufacturing Organizations
Region
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
Competitive Landscape
Key players competing in the global ibuprofen API market are Sino-US Zibo Xinhua-Perrigo Pharmaceutical Co., Ltd.; Solara Active Pharma Sciences Limited; Granules India Limited; BASF SE; BIOCAUSE Inc.; IOL Chemicals and Pharmaceuticals Limited; and SI Group, Inc.
- In May 2022, Strides received permission from the US Food and Drug Administration (USFDA) for ibuprofen oral suspension, expanding their ibuprofen brand’s reach in American markets.
- In February 2022, the sale of combination goods in Germany including paracetamol and ibuprofen without a prescription became possible after a revision to the drug prescription legislation was adopted by the Federal Council.
Request For Customization
Enquiry Before Buying
Speak With Analyst
